PRESS RELEASE published on 12/08/2025 at 14:53, 6 months 18 days ago EQS-Adhoc: Carl Zeiss Meditec AG: Termination of Maximilian Foerst’s Executive Board mandate as of 31 December 2025 and interim assumption of the CEO role by Andreas Pecher as of 1 January 2026 Carl Zeiss Meditec AG terminates Maximilian Foerst's Executive Board mandate on 31 December 2025 due to Code of Conduct violation. Andreas Pecher named interim CEO from 1 January 2026 Carl Zeiss Meditec AG Maximilian Foerst Andreas Pecher CEO Role Code Of Conduct Violation
BRIEF published on 08/07/2025 at 07:05, 10 months 19 days ago Carl Zeiss Meditec annonce une croissance de son chiffre d'affaires et de ses bénéfices pour 2024/25 Carl Zeiss Meditec Chiffre D'affaires 2024/25 Croissance En Ophtalmologie Ventes De Microchirurgie EMEA Et Amériques
BRIEF published on 08/07/2025 at 07:05, 10 months 19 days ago Carl Zeiss Meditec Reports Revenue and Earnings Growth for 2024/25 Carl Zeiss Meditec 2024/25 Revenue Ophthalmology Growth Microsurgery Sales EMEA And Americas
PRESS RELEASE published on 08/07/2025 at 07:00, 10 months 19 days ago Carl Zeiss Meditec grows revenue and earnings in the first nine months of 2024/25 Carl Zeiss Meditec AG reports revenue and earnings growth in the first nine months of 2024/25 fiscal year, with EBITA rising to €175.4m and positive contributions from various regions Revenue Growth Carl Zeiss Meditec Earnings Growth Fiscal Year 2024/25 Regional Contributions
BRIEF published on 05/13/2025 at 07:05, 1 year 1 month ago Carl Zeiss Meditec annonce une croissance de son chiffre d'affaires pour le premier semestre 2024/25 Carl Zeiss Meditec Croissance Des Revenus Ophtalmologie Tarifs Commerciaux Américains Acquisition De DORC
BRIEF published on 05/13/2025 at 07:05, 1 year 1 month ago Carl Zeiss Meditec Reports Revenue Growth for First Half of 2024/25 Revenue Growth Carl Zeiss Meditec Ophthalmology DORC Acquisition US Trade Tariffs
PRESS RELEASE published on 05/13/2025 at 07:00, 1 year 1 month ago Carl Zeiss Meditec achieves revenue growth and stable operating profit in the first six months of 2024/25 Carl Zeiss Meditec AG achieves revenue growth of 10.9% and stable operating profit in the first six months of 2024/25, with a significant order entry increase of 33.4% Revenue Growth Operating Profit Carl Zeiss Meditec AG Order Entry Increase Fiscal Year 2024/25
BRIEF published on 05/07/2025 at 15:25, 1 year 1 month ago Leadership Transition at Carl Zeiss Meditec AG Carl Zeiss Meditec Leadership Change Ophthalmology Maximilian Foerst Dr. Markus Weber
BRIEF published on 05/07/2025 at 15:25, 1 year 1 month ago Transition de direction chez Carl Zeiss Meditec AG Carl Zeiss Meditec Changement De Direction Ophtalmologie Maximilien Foerst Dr Markus Weber
PRESS RELEASE published on 05/07/2025 at 15:20, 1 year 1 month ago Change of President and CEO at Carl Zeiss Meditec AG Carl Zeiss Meditec AG announces change of President and CEO: Dr. Markus Weber steps down on 31 May 2025, to be succeeded by Maximilian Foerst on 1 June 2025. Foerst is currently Head of ZEISS Greater China Carl Zeiss Meditec AG President CEO Change Maximilian Foerst
Published on 06/26/2026 at 14:05, 1 hour 8 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 1 hour 13 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 2 hours 13 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 2 hours 28 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 14:00, 1 hour 13 minutes ago Hong Kong celebrates surge of global enterprises driving investment and opportunities
Published on 06/26/2026 at 14:00, 1 hour 13 minutes ago Bitcoin Group SE publishes 2025 Annual Report: Strategic realignment ensures future viability in the dynamic crypto market
Published on 06/26/2026 at 13:32, 1 hour 41 minutes ago Porsche ranks number one in J.D. Power 2026 U.S. Initial Quality Study
Published on 06/26/2026 at 13:30, 1 hour 42 minutes ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share
Published on 06/26/2026 at 13:30, 1 hour 43 minutes ago AlphaESS Unveils Expanded Energy Storage Ecosystem for Europe at Intersolar 2026
Published on 06/26/2026 at 07:00, 8 hours 13 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 8 hours 13 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
